Aromatase inhibitors (AIs) are becoming the hormonal treatment of choice for postmenopausal women with early breast cancer. Large, well-controlled clinical studies have established the efficacy ...

The FDA will decide whether to approve a once-daily, 25 mg oral formulation of semaglutide (Wegovy) by the end of 2025. If ...

Panelists discuss how testing for specific changes in cancer cells, like ESR1 mutations, can help guide treatment choices for ...

Balancing estrogen isn’t just about cutting soy—it’s about strategic, science-backed foods that go beyond the basics ...

Breast health, including breast cancer early detection and prevention, assessing and managing breast skin changes, and premature breast development ...

LTRN A May 5th press release indicated that the FDA cleared Lantern Pharma, Inc.’s (NASDAQ:LTRN) LP-184 trial in triple ...

Truqap can be used in patients whose disease has progressed despite prior endocrine therapy with a CDK 4/6 inhibitor and an aromatase inhibitor, according to a newly published guidance document.

Venoarterial Extracorporeal membrane oxygenation (VA ECMO) for extracorporeal cardiopulmonary resuscitation (ECPR) in adults in refractory cardiac arrest Interventional procedure consultation ...

to regimens of CDK4/6 inhibitors with aromatase inhibitors like anastrozole or letrozole. According to one of the study's principal investigators – François-Clément Bidard of the Institut ...

12 A rigorous large-scale randomised controlled trial published recently reported that true acupuncture, compared with sham acupuncture or waitlist control, resulted in a significant reduction in ...

In recent years, the treatment landscape of HR+/HER2−ve breast cancer has completely changed with the introduction of particularly active targeted drugs, from CDK4/6 inhibitors, mTOR inhibitors, and ...